Novartis News & Analysen

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen
			Ausblick

17.02.21

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease (GlobeNewswire)

16.02.21

Novartis Entresto® granted expanded indication in chronic heart failure by FDA (GlobeNewswire)

11.02.21

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics (GlobeNewswire)

29.01.21

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis (GlobeNewswire)

26.01.21

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. (GlobeNewswire)

26.01.21

Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben (GlobeNewswire)

26.01.21

Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben (Novartis)

26.01.21

Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben (Novartis AG)

11.01.21

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene (GlobeNewswire)

18.12.20

Novartis receives complete response letter from U.S. FDA for inclisiran (GlobeNewswire)

16.12.20

Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF (GlobeNewswire)

15.12.20

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema (GlobeNewswire)

14.12.20

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 (GlobeNewswire)

09.12.20

Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer (GlobeNewswire)

09.12.20

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer (GlobeNewswire)

08.12.20

Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial (GlobeNewswire)

05.12.20

Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas (GlobeNewswire)

04.12.20

Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD (GlobeNewswire)

24.11.20

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event (GlobeNewswire)

19.11.20

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy (GlobeNewswire)

19.11.20

New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases (GlobeNewswire)

19.11.20

Novartis set to achieve 100% renewable electricity in its European operations (GlobeNewswire)

13.11.20

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender (GlobeNewswire)

06.11.20

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) (GlobeNewswire)

05.11.20

Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study (GlobeNewswire)

02.11.20

Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention (GlobeNewswire)

30.10.20

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia (GlobeNewswire)

28.10.20

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 (GlobeNewswire)

27.10.20

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance. (GlobeNewswire)

27.10.20

Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben (GlobeNewswire)

27.10.20

Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben (Novartis)

27.10.20

Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben (Novartis AG)

26.10.20

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G) (GlobeNewswire)

16.10.20

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol (GlobeNewswire)

01.10.20

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement (GlobeNewswire)

23.09.20

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)

23.09.20

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program (GlobeNewswire)

19.09.20

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation (GlobeNewswire)

19.09.20

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma (GlobeNewswire)

16.09.20

Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM (GlobeNewswire)

16.09.20

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond (GlobeNewswire)

14.09.20

European Medicines Agency (EMA) approves safety label update for Novartis Beovu® (GlobeNewswire)

14.09.20

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) (GlobeNewswire)

11.09.20

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) (GlobeNewswire)

11.09.20

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis (GlobeNewswire)

08.09.20

Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum (GlobeNewswire)

07.09.20

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings (GlobeNewswire)

01.09.20

Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality (GlobeNewswire)

30.08.20

Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran (GlobeNewswire)

29.08.20

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH) (GlobeNewswire)

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

LafargeHolcim	51.90	3.47 %
The Swatch Grp	279.90	3.21 %
Part Grp Hldg	1’123.50	3.03 %
ABB	26.79	2.57 %
Sika	246.00	2.41 %
Zurich Insur Gr	376.40	1.32 %
Givaudan	3’472.00	1.31 %
Swisscom	461.80	1.16 %
Roche Hldg G	300.25	0.77 %
Lonza Grp	575.60	0.31 %

22:13		J&J-Aktie stärker: Impfstoff von Johnson & Johnson erhält Notfallzulassung in den USA
22:10		Aktien uneins: AstraZeneca verkauft anscheinend Moderna-Beteiligung
17:52		Roche-Aktie stärker: Corona-Test zur Eigenanwendung in Deutschland zugelassen - Investition in deutsche Standorte
15:48		AstraZeneca-Impfstau droht weiter zu wachsen
12:50		Merck erwirbt Lizenz für Krebsmittelkandidat Xevinapant von Debiopharm
28.02.21		Merck-Aktie: Experten empfehlen Merck im Februar mehrheitlich zum Kauf
28.02.21		So schätzen die Analysten die Sanofi-Aktie im Februar 2021 ein

Nachrichten zu Novartis AG

Eintrag hinzufügen Eintrag bearbeiten

Aktien Top/Flop

Novartis Peer Group Nachrichten

Meistgelesene Nachrichten